TAK-070

a noncompetitive BACE1/beta-site APP cleaving enzyme 1 inhibitor; structure in first source

Also Known As:

(R)-6-((1,1'-biphenyl)-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-2-naphthalene-ethan-amine hydrochloride monohydrate; (R)-6-((1,1'-biphenyl)-4-ylmethoxy)-1,2,3,4-tetrahydro-N,N-dimethyl-2-naphthaleneethanamine hydrochloride monohydrate

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Fukumoto, Hiroaki: 2 articles (11/2010 - 08/2010)
2.	Kato, Kaneyoshi: 2 articles (11/2010 - 08/2010)
3.	Maeda, Ryouta: 2 articles (11/2010 - 08/2010)
4.	Miyamoto, Masaomi: 2 articles (11/2010 - 08/2010)
5.	Takahashi, Hideki: 2 articles (11/2010 - 08/2010)
6.	Terauchi, Jun: 2 articles (11/2010 - 08/2010)
7.	Hirai, Kazuko: 1 article (08/2010)
8.	Hirode, Mitsuhiro: 1 article (08/2010)
9.	Iwatsubo, Takeshi: 1 article (08/2010)
10.	Kakihana, Mitsuru: 1 article (08/2010)

Related Diseases

Alzheimer Disease (Alzheimer's Disease)

08/18/2010 - "A noncompetitive BACE1 inhibitor TAK-070 ameliorates Abeta pathology and behavioral deficits in a mouse model of Alzheimer's disease."
11/18/2010 - "Our findings support the idea that partial inhibition of BACE1 by TAK-070 exerts symptomatic as well as disease-modifying effects for the treatment of Alzheimer's disease."
08/18/2010 - "We discovered a nonpeptidic compound, TAK-070, that inhibited BACE1, a rate-limiting protease for the generation of Abeta peptides that are considered causative for Alzheimer's disease (AD), in a noncompetitive manner. "

Related Drugs and Biologics

1.	Peptides (Polypeptides)
2.	Peptide Hydrolases (Proteases)